SAREPTA THERAPEUTICS, INC. Other Accrued Liabilities, Current
SAREPTA THERAPEUTICS, INC. (SRPT) had Other Accrued Liabilities, Current of $5.47 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:OtherAccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Other Accrued Liabilities, Current $5.47M.
- 2026-03-31: Other Accrued Liabilities, Current $4.63M.
- 2025-12-31: Other Accrued Liabilities, Current $6.96M; Other Accrued Liabilities, Current as first filed $7.96M.
- 2025-09-30: Other Accrued Liabilities, Current $10.24M.
| Period end | Other Accrued Liabilities, Current | Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $5.47M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $4.63M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $6.96M 10-Q · filed 2026-08-05 | $7.96M 10-K · filed 2026-03-02 |
| 2025-09-30 | $10.24M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $5.93M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $10.02M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $12.65M 10-K · filed 2026-03-02 | $5.34M 10-K · filed 2025-02-28 |
| 2024-09-30 | $5.39M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $4.99M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $5.88M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $6.47M 10-K · filed 2025-02-28 | $8.63M 10-K · filed 2024-02-28 |
| 2023-09-30 | $7.72M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $9.79M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $4.36M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $5.31M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $4.34M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $6.57M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $3.96M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $5.39M 10-K · filed 2023-02-28 | $5.61M 10-K · filed 2022-03-01 |
| 2021-09-30 | $6.04M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $4.35M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $3.95M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $9.46M 10-K · filed 2022-03-01 | $4.47M 10-K · filed 2021-03-01 |
| 2020-09-30 | $4.78M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $5.35M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $8.21M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $4.78M 10-K · filed 2021-03-01 | $7.01M 10-K · filed 2020-02-26 |
| 2019-09-30 | $2.64M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $3.40M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $3.59M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $10.31M 10-K · filed 2020-02-26 | $2.47M 10-K · filed 2019-02-28 |
| 2018-09-30 | $444.00K 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $1.41M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $2.86M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $2.48M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $2.92M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $3.85M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $4.04M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $1.99M 10-K · filed 2018-03-01 | $3.58M 10-K · filed 2017-02-28 |
| 2016-09-30 | $1.17M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $2.55M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $722.00K 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $1.56M 10-K · filed 2017-02-28 | $1.43M 10-K · filed 2016-02-25 |
| 2015-09-30 | $1.30M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $735.00K 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $693.00K 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $440.00K 10-K · filed 2016-02-25 | |
| 2014-09-30 | $784.00K 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $730.00K 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $800.00K 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $1.28M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |